This epigenetic modulation by acetylated KLF5 unveils a therapeutic opportunity; the concurrent administration of docetaxel and the CXCR4 inhibitor plerixafor has shown efficacy in curbing ac‐KLF5‐driven bone metastasis and enhancing tumor response to chemotherapy.236. This evidence concerns the gene KLF5 and neoplasm.